

From: [Tran, Frank](#)
To: [Todd Hockemeyer](#)
Subject: Request for additional information regarding NRC license application for POINT Biopharma U.S. Inc.
Date: Friday, February 26, 2021 2:33:00 PM

Dear Mr. Hockemeyer:

In your application, you requested 5 curies of actinium-225 in solid or liquid form. It appears that actinium-225 is not listed in 10 CFR 30.72, "Schedule C—Quantities of radioactive materials requiring consideration of the need for an emergency plan for responding to a release". Therefore, by default we select "Any other alpha emitter" which is limited to 2 curies maximum. Your total possession limit including actinium-225 and other applicable isotopes has exceeded the unity or 1 (see footnote 1 of 10 CFR 30.72). Based on the requirement set forth in 10 CFR 30.32(i), the applicant must include an emergency plan in accordance with the requirement in this section in its application.

Based on the above, please review the requirement in 10 CFR 30.32(i) and provide the response for the following.

1. Provide an emergency plan in accordance with 10 CFR 30.32(i) and Regulatory Guide 3.67, "Standard Format and Content for Emergency Plans for Fuel Cycle and Materials Facilities"; or
2. Reduce the maximum of licensed material quantity to below the unity as stated in 10 CFR 30.72 (for example, decrease the actinium-225 in your application to below 1.8 curies, etc.)

Please provide the response to the above in writing with signature by March 5, 2021. If you need additional time, please let me know. You could mail the response to NRC Region III, Materials Licensing Branch, 2443 Warrenville Road, Suite 210, Lisle, IL 60532 or fax to 630-515-1078. To facilitate proper mail handling in our office, please reference Mail Control No. 621132 in the cover letter.

If you have any questions, please contact me at 630-829-9623 or reply to this email.

Thank you,

Frank Tran